[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: chronic progressive bilateral ulnar sensorimotor deficits, demyelinating features (conduction block, temporal dispersion), negative anti-ganglioside antibodies, elevated CSF protein. The findings are symmetric and bilateral, which is classic for chronic inflammatory demyelinating polyneuropathy (CIDP). Lewis-Sumner syndrome (D) is an asymmetric multifocal variant, making it a less likely best answer given the symmetric presentation. The keyed answer (D) is not the single best answer; option B (CIDP) is more defensible. Main medical accuracy issue: none; the pathophysiology is accurate. Minimal fix: Change the key to B (CIDP) or, to make D correct, edit the vignette to describe asymmetric involvement of individual nerves.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: chronic progressive bilateral ulnar sensorimotor deficits, demyelinating features (conduction block, temporal dispersion), negative anti-ganglioside antibodies, elevated CSF protein. The findings are symmetric and bilateral, which is classic for chronic inflammatory demyelinating polyneuropathy (CIDP). Lewis-Sumner syndrome (D) is an asymmetric multifocal variant, making it a less likely best answer given the symmetric presentation. The keyed answer (D) is not the single best answer; option B (CIDP) is more defensible. Main medical accuracy issue: none; the pathophysiology is accurate. Minimal fix: Change the key to B (CIDP) or, to make D correct, edit the vignette to describe asymmetric involvement of individual nerves.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Postpartum TMA with ADAMTS13 >10% (ruling out TTP), non-resolution after delivery, and new neurological symptoms point to complement-mediated TMA (aHUS). The most direct and specific finding supporting eculizumab initiation is evidence of complement dysregulation. Option D (Low C3 with normal C4) is a strong, immediate laboratory marker of alternative pathway activation, consistent with aHUS and eculizumab use. Option B (Factor H mutation) is confirmatory but is a genetic test result, which is not typically available urgently to guide acute therapy initiation. This creates a miskeying issue where D is the more clinically relevant and supportive acute finding. Medical accuracy is sound. Minimal fix: Change key to D or rephrase the question to ask for the 'most specific confirmatory test' rather than the finding that 'most strongly supports initiating' acute therapy.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. Key stem clues: Postpartum TMA with ADAMTS13 >10% (ruling out TTP), non-resolution after delivery, and new neurological symptoms point to complement-mediated TMA (aHUS). The most direct and specific finding supporting eculizumab initiation is evidence of complement dysregulation. Option D (Low C3 with normal C4) is a strong, immediate laboratory marker of alternative pathway activation, consistent with aHUS and eculizumab use. Option B (Factor H mutation) is confirmatory but is a genetic test result, which is not typically available urgently to guide acute therapy initiation. This creates a miskeying issue where D is the more clinically relevant and supportive acute finding. Medical accuracy is sound. Minimal fix: Change key to D or rephrase the question to ask for the 'most specific confirmatory test' rather than the finding that 'most strongly supports initiating' acute therapy.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: hypertrophic cardiomyopathy with LVOT gradient 85 mmHg, recurrent VT despite maximal medical therapy, extensive LGE (18%), and moderate MR with SAM. The question asks for the intervention most likely to reduce arrhythmia burden in this high-risk substrate with obstruction. Surgical myectomy (B) is the keyed answer and is defensible as best: it directly reduces obstruction (a potential VT trigger), allows mitral repair, and avoids the proarrhythmic scar of alcohol ablation. Alternatives are inferior: alcohol ablation (A) adds proarrhythmic scar; VT ablation (C) treats the arrhythmia but not the underlying obstruction; amiodarone (D) adds toxicity without addressing the structural issue; transplant (E) is premature. The item is logically valid and medically accurate, aligning with guidelines that favor myectomy over ablation in young patients with significant LGE and VT. Minimal fix: none required.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: hypertrophic cardiomyopathy with LVOT gradient 85 mmHg, recurrent VT despite maximal medical therapy, extensive LGE (18%), and moderate MR with SAM. The question asks for the intervention most likely to reduce arrhythmia burden in this high-risk substrate with obstruction. Surgical myectomy (B) is the keyed answer and is defensible as best: it directly reduces obstruction (a potential VT trigger), allows mitral repair, and avoids the proarrhythmic scar of alcohol ablation. Alternatives are inferior: alcohol ablation (A) adds proarrhythmic scar; VT ablation (C) treats the arrhythmia but not the underlying obstruction; amiodarone (D) adds toxicity without addressing the structural issue; transplant (E) is premature. The item is logically valid and medically accurate, aligning with guidelines that favor myectomy over ablation in young patients with significant LGE and VT. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n    \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: anti-MDA5+ dermatomyositis, new ground-glass opacities, low DLCO, and progressive dyspnea despite initial therapy, defining rapidly progressive interstitial lung disease (RP-ILD). The item correctly identifies this as a high-mortality scenario requiring aggressive immunosuppression. Main logical issue: None. Main medical accuracy issue: None; the triple therapy recommendation aligns with current consensus guidelines and literature for anti-MDA5-associated RP-ILD. Minimal fix: None required; the item is clear, accurate, and supports a single best answer.\",\n    \"logical_false_reason\": \"T\",\n    \"logical_validity\": true,\n    \"medical_accuracy_score\":", "judge_output_valid": false, "judge_parse_error": "json decode error: Expecting value: line 5 column 30 (char 747)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: HIV-associated cryptococcal meningitis with initial high opening pressure, worsening symptoms and pressure after 10 days of appropriate antifungal therapy, decreasing antigen titer (1:2048 to 1:1024) indicating treatment response, absence of ART initiation (precluding IRIS). The item correctly identifies persistent elevated intracranial pressure as the primary problem despite antifungal response. The keyed answer (D) is the standard of care: continue antifungals and intensify CSF drainage. Alternatives are incorrect: steroids are contraindicated (A), antigen decrease argues against antifungal resistance (B), shunt is premature before optimizing drainage (C), and early ART increases mortality risk (E). No logical contradictions or missing details. Minimal fix: none required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: HIV-associated cryptococcal meningitis with initial high opening pressure, worsening symptoms and pressure after 10 days of appropriate antifungal therapy, decreasing antigen titer (1:2048 to 1:1024) indicating treatment response, absence of ART initiation (precluding IRIS). The item correctly identifies persistent elevated intracranial pressure as the primary problem despite antifungal response. The keyed answer (D) is the standard of care: continue antifungals and intensify CSF drainage. Alternatives are incorrect: steroids are contraindicated (A), antigen decrease argues against antifungal resistance (B), shunt is premature before optimizing drainage (C), and early ART increases mortality risk (E). No logical contradictions or missing details. Minimal fix: none required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Progressive cognitive decline, multifocal non-enhancing white matter lesions, positive JC virus PCR (confirming PML), followed by clinical and radiographic worsening (new enhancement, edema, increased CSF pleocytosis) after stopping immunosuppressive adalimumab. This classic sequence supports PML-IRIS. Main logical issue: None; the vignette provides a clear temporal and clinical pattern. Main medical accuracy issue: None; the management aligns with standard guidelines for PML-IRIS. Minimal fix: None required; the item is clear, accurate, and supports a single best answer.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Progressive cognitive decline, multifocal non-enhancing white matter lesions, positive JC virus PCR (confirming PML), followed by clinical and radiographic worsening (new enhancement, edema, increased CSF pleocytosis) after stopping immunosuppressive adalimumab. This classic sequence supports PML-IRIS. Main logical issue: None; the vignette provides a clear temporal and clinical pattern. Main medical accuracy issue: None; the management aligns with standard guidelines for PML-IRIS. Minimal fix: None required; the item is clear, accurate, and supports a single best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: Behçet's disease (oral/genital ulcers, uveitis, HLA-B51) with severe ocular complication (retinal artery occlusion from vasculitis, confirmed by angiography). The question asks for the most appropriate immediate intervention to prevent contralateral involvement, which is a severe, vision-threatening inflammatory event. The keyed answer (D) aligns with current guidelines for severe ocular Behçet, which recommend high-dose corticosteroids combined with a TNF-alpha inhibitor (infliximab or adalimumab) for rapid, aggressive immunosuppression. Alternatives are inferior: A (steroids alone) is insufficient; B (infliximab alone) typically requires steroid bridge; C (cyclosporine) is slower and less effective for this acuity; E (paracentesis/massage) is for embolic, not inflammatory, occlusion. No logical contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; item is valid and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: Behçet's disease (oral/genital ulcers, uveitis, HLA-B51) with severe ocular complication (retinal artery occlusion from vasculitis, confirmed by angiography). The question asks for the most appropriate immediate intervention to prevent contralateral involvement, which is a severe, vision-threatening inflammatory event. The keyed answer (D) aligns with current guidelines for severe ocular Behçet, which recommend high-dose corticosteroids combined with a TNF-alpha inhibitor (infliximab or adalimumab) for rapid, aggressive immunosuppression. Alternatives are inferior: A (steroids alone) is insufficient; B (infliximab alone) typically requires steroid bridge; C (cyclosporine) is slower and less effective for this acuity; E (paracentesis/massage) is for embolic, not inflammatory, occlusion. No logical contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: progressive weakness with areflexia, preceding diarrheal illness, NCS showing axonal pattern (reduced CMAP, normal velocities), anti-GM1 positivity, and clinical deterioration despite IVIG with new respiratory failure. The item clearly describes a severe, IVIG-refractory Guillain-Barré syndrome (AMAN variant). The logical flow is sound: IVIG failed, so the next step is a different, established therapy. Plasma exchange (PLEX) is the standard second-line intervention per guidelines. Main medical accuracy issue: Minor nuance—eculizumab is an emerging option for refractory cases, but labeling PLEX as the next best step is accurate and standard. Minimal fix: None required for logical validity; to enhance precision, the stem could specify 'despite a full 5-day course of IVIG (2 g/kg total)' to preempt questions about adequacy of initial therapy.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: progressive weakness with areflexia, preceding diarrheal illness, NCS showing axonal pattern (reduced CMAP, normal velocities), anti-GM1 positivity, and clinical deterioration despite IVIG with new respiratory failure. The item clearly describes a severe, IVIG-refractory Guillain-Barré syndrome (AMAN variant). The logical flow is sound: IVIG failed, so the next step is a different, established therapy. Plasma exchange (PLEX) is the standard second-line intervention per guidelines. Main medical accuracy issue: Minor nuance—eculizumab is an emerging option for refractory cases, but labeling PLEX as the next best step is accurate and standard. Minimal fix: None required for logical validity; to enhance precision, the stem could specify 'despite a full 5-day course of IVIG (2 g/kg total)' to preempt questions about adequacy of initial therapy.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: acute ischemic stroke with LVO (M1 occlusion), onset 90 min, no hemorrhage, large penumbra, INR 2.8 (therapeutic). The keyed answer (B) correctly identifies that IV alteplase is contraindicated due to therapeutic INR >1.7, and thrombectomy is indicated. However, the most appropriate next step is to reverse anticoagulation (with 4-factor PCC) and then administer IV alteplase if possible, as per current AHA/ASA guidelines (2023) which allow IV thrombolysis after reversal in select patients with mechanical heart valves. Option C is the guideline-supported best answer. Main logical issue: key mismatch. Main medical accuracy issue: the rationale incorrectly states reversal adds delay and increases bleeding risk, which contradicts guideline recommendations. Minimal fix: Change the key to C and update the rationale to reflect current guideline-supported reversal and thrombolysis pathway.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: acute ischemic stroke with LVO (M1 occlusion), onset 90 min, no hemorrhage, large penumbra, INR 2.8 (therapeutic). The keyed answer (B) correctly identifies that IV alteplase is contraindicated due to therapeutic INR >1.7, and thrombectomy is indicated. However, the most appropriate next step is to reverse anticoagulation (with 4-factor PCC) and then administer IV alteplase if possible, as per current AHA/ASA guidelines (2023) which allow IV thrombolysis after reversal in select patients with mechanical heart valves. Option C is the guideline-supported best answer. Main logical issue: key mismatch. Main medical accuracy issue: the rationale incorrectly states reversal adds delay and increases bleeding risk, which contradicts guideline recommendations. Minimal fix: Change the key to C and update the rationale to reflect current guideline-supported reversal and thrombolysis pathway.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: peripartum cardiomyopathy (PPCM) with TTN truncating variant, LVEF improved from 25% to 40% on GDMT, question asks for strongest predictor of *complete* LV recovery. The item correctly identifies absence of LGE on cardiac MRI as the strongest predictor, as LGE indicates irreversible fibrosis. The TTN variant (C) is a distractor, as it predicts *incomplete* recovery. Options B, D, and E are less predictive. Medical accuracy is sound, aligning with current literature on PPCM prognosis. Logical validity is intact: a single best answer is defensible based on established evidence. Minimal fix: none required; item is well-constructed.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: peripartum cardiomyopathy (PPCM) with TTN truncating variant, LVEF improved from 25% to 40% on GDMT, question asks for strongest predictor of *complete* LV recovery. The item correctly identifies absence of LGE on cardiac MRI as the strongest predictor, as LGE indicates irreversible fibrosis. The TTN variant (C) is a distractor, as it predicts *incomplete* recovery. Options B, D, and E are less predictive. Medical accuracy is sound, aligning with current literature on PPCM prognosis. Logical validity is intact: a single best answer is defensible based on established evidence. Minimal fix: none required; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]